Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

9.58
+0.81009.24%
Post-market: 9.600.0200+0.21%19:54 EDT
Volume:4.08M
Turnover:36.85M
Market Cap:517.33M
PE:-3.00
High:9.59
Open:9.13
Low:8.50
Close:8.77
52wk High:11.72
52wk Low:1.45
Shares:54.00M
Float Shares:40.09M
Volume Ratio:4.11
T/O Rate:10.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1956
EPS(LYR):-3.0934
ROE:-75.32%
ROA:-41.91%
PB:3.74
PE(LYR):-3.10

Loading ...

Company Profile

Company Name:
Lexeo Therapeutics
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
61
Office Location:
345 Park Avenue South,6th Floor,New York,New York,United States
Zip Code:
10010
Fax:
- -
Introduction:
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Directors

Name
Position
R. Nolan Townsend
Director and Chief Executive Officer
Steven Altschuler
Chairman of the Board
Brenda Cooperstone
Independent Director
Mette Kirstine Agger
Independent Director
Paula HJ Cholmondeley
Independent Director
Reinaldo Diaz
Independent Director
Tim Van Hauwermeiren
Independent Director
Tolga Tanguler
Independent Director

Shareholders

Name
Position
R. Nolan Townsend
Director and Chief Executive Officer
Louis Tamayo
Chief Financial Officer
Eric Adler
Chief Medical Officer and Head, Research
Jenny R. Robertson
Chief Legal Officer
Jose Manuel Otero
Chief Technical Officer
Sandi See Tai
Chief Development Officer